Hims & Hers Health, Inc. (NYSE:HIMS) Shares Bought by American Century Companies Inc.

American Century Companies Inc. increased its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,758 shares of the company's stock after acquiring an additional 11,425 shares during the period. American Century Companies Inc. owned approximately 0.06% of Hims & Hers Health worth $3,404,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of HIMS. Crewe Advisors LLC acquired a new stake in Hims & Hers Health in the fourth quarter valued at $28,000. Raleigh Capital Management Inc. boosted its position in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its position in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, US Bancorp DE increased its holdings in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after acquiring an additional 1,508 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In other news, insider Irene Becklund sold 2,203 shares of Hims & Hers Health stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the sale, the insider now directly owns 8,007 shares of the company's stock, valued at approximately $230,441.46. The trade was a 21.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Melissa Baird sold 33,337 shares of the stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $27.32, for a total value of $910,766.84. Following the completion of the transaction, the chief operating officer now directly owns 805,083 shares of the company's stock, valued at $21,994,867.56. This represents a 3.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 835,884 shares of company stock valued at $31,659,701. 17.71% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Morgan Stanley lowered Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their target price for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Canaccord Genuity Group increased their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Bank of America boosted their price target on Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a report on Tuesday, March 18th. Finally, Needham & Company LLC increased their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $38.25.

Hims & Hers Health Price Performance

NYSE:HIMS traded up $0.32 during mid-day trading on Friday, reaching $27.13. The company's stock had a trading volume of 16,210,541 shares, compared to its average volume of 15,109,285. The stock has a market cap of $6.03 billion, a P/E ratio of 61.66 and a beta of 1.65. The company's fifty day simple moving average is $38.75 and its two-hundred day simple moving average is $30.37. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.